EGFR and head and neck squamous cell carcinoma: KEYNOTE-055 support the safety, tolerability and anti-tumour activity of pembrolizumab as a monotherapy in patients with HNSCC with disease progression on platinum-based and cetuximab (EGFR mAb) therapy [441].